Liquidia Technologies Inc (LQDA : NASDAQ)
Common Stock
$33.94
USD
+7.13 (26.59%)
Last updated: 2026-10-14
Follow LQDA
LQDA
Liquidia Technologies Inc
WealthAwesomePerformance
1 Day
+26.59%
1 Week
+27.21%
1 Month
-48.03%
YTD
-50.56%
Key Statistics
Market Cap
$3.04B
52W High
$93.61
52W Low
$21.94
P/E Ratio
24.42
50 Day MA
$62.71
200 Day MA
$53.93
Beta
0.61
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/14/2026 | $35.70 | $38.64 | $33.12 | $33.94 | $33.94 | 21,143,436 |
| 10/13/2026 | $27.04 | $27.40 | $26.13 | $26.81 | $26.81 | 7,653,314 |
| 10/12/2026 | $29.27 | $30.86 | $27.27 | $27.67 | $27.67 | 4,305,710 |
| 10/9/2026 | $27.06 | $28.53 | $26.67 | $27.38 | $27.38 | 3,580,500 |
| 10/8/2026 | $26.34 | $29.35 | $26.34 | $28.02 | $28.02 | 5,231,455 |
| 10/7/2026 | $25.55 | $27.33 | $24.59 | $26.68 | $26.68 | 6,959,541 |
| 10/6/2026 | $27.95 | $28.30 | $25.76 | $25.91 | $25.91 | 5,286,559 |
| 10/5/2026 | $28.07 | $28.48 | $25.92 | $27.64 | $27.64 | 7,746,547 |
| 10/2/2026 | $26.69 | $29.18 | $26.31 | $28.64 | $28.64 | 8,394,700 |
| 10/1/2026 | $23.96 | $28.10 | $22.31 | $27.99 | $27.99 | 21,573,271 |
Analyst Price Targets
Based on 8 analysts covering LQDA · as of Oct 15, 2026
Wall Street analysts forecast LQDA stock price to rise 57.6% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
US$53.50
+57.6% Upside
Previously US$49.33 on Oct 12, 2026
Current Price
US$33.94
Last close
Analyst Breakdown (8 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LQDA's historical volatility
30-Day Vol
262.9%
Annualized
90-Day Vol
166.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$28.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$31.98 | US$12.91 – US$79.21 |
| 60 trading days | US$30.13 | US$8.35 – US$108.67 |
| 90 trading days | US$28.39 | US$5.90 – US$136.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Financials
- Revenue (TTM)
- $450.91M
- EBITDA
- $169.77M
- Profit Margin
- 30.74%
- ROE (TTM)
- 131.82%
- EPS (Diluted)
- 1.39
- Book Value
- 2.19
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About LQDA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NVNI | Nvni Group Limited Ordinary Shares | $0.53 | +382.56% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +150.56% |
| SOBR | Sobr Safe Inc | $0.08 | +94.88% |
| GLND | Greenland Energy Company Common Stock | $3.90 | +76.47% |
| TGL | Treasure Global Inc. | $0.45 | +61.87% |
| NIVF | NewGenIvf Group Limited Class A Ordinary Shares | $0.29 | +50.20% |
| CRANR | Crane Harbor Acquisition Corp. II Rights | $0.16 | +45.47% |
| HCICR | Hennessy Capital Investment Corp. VIII Share Rights | $0.12 | +41.53% |
LQDA.US news timeline
5 articles covering LQDA.US, most recent first
Latest